04.06.2013 - Active Biotech's immunotoxin naptumomab estafenatox has doubled overall survival in renal cell cancer patients.
A combination therapy of Active Biotech's fusion protein naptumomab estafenatox (ABR-217620), plus interferon-alpha, extended overall survival in a patient subgroup of the ANYARA Phase II/III study to 63.3 compared to 31.1 months in the interferon-alpha arm. The drug is a new class of fusion protein, which links a FAB fragment of an antibody that specifically binds to the 5T4 antigen on tumour cells with the superantigen staphylococcal enterotoxin, that induces a tumour-specific T-cell immune response.
Statistically significant benefit, however, was only achieved when patients with high levels of pre-formed antibodies against superantigens or the cytokine IL-6 were excluded. In this subgroup of 131 patients, progression-free survival improved from 5.8 months in the interferon-alpha arm to 8.5 months in the naptumomab estafenatox - interferon-alpha arm. Active Biotech is now seeking a partner for Phase III development of the targeted cancer therapy"
Renal Cell Carcinoma (RCC) affects approximately 180,000 people worldwide each year. Approximately 50 % of the patients are affected by metastases. If the disease has metastasized, average survival is around 2 years. The survival rate of patients diagnosed with renal cancer is only 5-15% after five years. The market for treatment of RCC is estimated at approximately US$2.7bn per year (EvaluatePharma March 2012). Approved first-line treatments are Sutent, Avastin in combination with IFN, Torisel and Votrient. Authorised second-line treatment are Nexavar and Everolimus.
03.07.2015 Biotech giant Biogen is investing CHF 1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, the new plant will create up to 400 jobs.
02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.
30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.
24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.
22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.
12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.
METTLER TOLEDO now offers a new family of high-precision weighing platforms that provide superior accuracy and reliability in harsh industrial conditions with flexibility to be used for many applications. more